Charting the course for CAR T-cell manufacturing
Magdi Elsallab, Marcela V. Maus · 2024
Read Charting the course for CAR T-cell manufacturing by Magdi Elsallab, Marcela V. Maus (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11707393.txt.
Description
Magdi Elsallab and Marcela Maus chart the debate over where engineered immune cells should be made, in a 2024 commentary. CAR T-cell therapy reprograms a patient's own cells to hunt cancer, but making them is slow and centralized. The commentary gathers three viewpoints printed alongside it. Making cells at the hospital could be the sole route to fair access. The commercial factory model, others argue, is what scales a therapy up and spreads it.
A third view sees the two models as partners rather than rivals. Hospital production is already running in India and is expected in Brazil. How this manufacturing question settles will decide who in the world actually receives these transformative treatments.
Catalog record
| CREATOR | Magdi Elsallab, Marcela V. Maus |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 6 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |